Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR) - 07/07/09
, A. Rodriguez-Morales b, 1, J. Diels c, 1, M. Povey d, 1, A. Jacobs e, 1, Z. Zhao e, 1, A. Lam e, 1
Corresponding author. Servicio de Psiquiatria, Hospital Meixoeiro, Complejo Hospitalario Universitario de Vigo, 36200, Spain. Tel.: +34 986811100; fax: +34 986811138.Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 10 |
| Iconographies | 4 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Background |
The electronic Schizophrenia Treatment Adherence Registry (e-STAR) is a prospective, observational study of patients with schizophrenia designed to evaluate long-term treatment outcomes in routine clinical practice.
Methods |
Parameters were assessed at baseline and at 3 month intervals for 2 years in patients initiated on risperidone long-acting injection (RLAI) (n=1345) or a new oral antipsychotic (AP) (n=277; 35.7% and 36.5% on risperidone and olanzapine, respectively) in Spain. Hospitalization prior to therapy was assessed by a retrospective chart review.
Results |
At 24 months, treatment retention (81.8% for RLAI versus 63.4% for oral APs, p<0.0001) and reduction in Clinical Global Impression Severity scores (−1.14 for RLAI versus −0.94 for APs, p=0.0165) were significantly higher with RLAI. Compared to the pre-switch period, RLAI patients had greater reductions in the number (reduction of 0.37 stays per patient versus 0.2, p<0.05) and days (18.74 versus 13.02, p<0.01) of hospitalizations at 24 months than oral AP patients.
Conclusions |
This 2 year, prospective, observational study showed that, compared to oral antipsychotics, RLAI was associated with better treatment retention, greater improvement in clinical symptoms and functioning, and greater reduction in hospital stays and days in hospital in patients with schizophrenia. Improved treatment adherence, increased efficacy and reduced hospitalization with RLAI offer the opportunity of substantial therapeutic improvement in schizophrenia.
Le texte complet de cet article est disponible en PDF.Keywords : Risperidone long-acting injection, Antipsychotic medication, Schizophrenia, Treatment retention, Observational study
Plan
 | Parts of this study have been presented at the Association of European Psychiatrists 16th European Congress of Psychiatry, April 5–9, 2008, Nice, France, and the American Psychiatric Association’s 161st annual meeting, May 3–8, 2008, Washington DC, USA. |
Vol 24 - N° 5
P. 287-296 - juin 2009 Retour au numéro
Article précédent
- Cannabis use and age of diagnosis of schizophrenia
- Gisela Sugranyes, Itziar Flamarique, Eduard Parellada, Immaculada Baeza, Javier Goti, Emilio Fernandez-Egea, Miquel Bernardo
- Predictors of response to group cognitive-behavioral therapy in the treatment of obsessive-compulsive disorder
- Andréa Litvin Raffin, Jandyra Maria Guimarães Fachel, Ygor Arzeno Ferrão, Fernanda Pasquoto de Souza, Aristides Volpato Cordioli
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?